Equity · Healthcare
GLUE
NASDAQMonte Rosa Therapeutics (GLUE)
The line runs 16 USD on 12 August through 13.37 USD on 28 August, on a scale from 13 to 17. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.1B USD
- Revenue, year to Dec 2025
- 123.7M USD
- 52-week range
- 4.51 USD – 25 USD
- Avg volume
- 241.7K
as of Aug 28, 2026
Have Monte Rosa Therapeutics (GLUE) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Monte Rosa Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 2 Jan 2026, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 5 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Oct 2026 | Bowen MatthewPrincipal Accounting Officer | Sell | 13 | 137 USD |
Which funds hold Monte Rosa Therapeutics (GLUE)?
1 of the 45 institutional funds we track reported a Monte Rosa Therapeutics position for the quarter ended 30 Sep 2026 — a combined 3.5M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 295,844 | 3.5M USD | −18.6% |
What has been filed or recorded for Monte Rosa Therapeutics (GLUE)?
The filings we hold for Monte Rosa Therapeutics, newest first: 1 fails-to-deliver day and 4 reported financial figures, the latest dated 02 Oct 2026.
| And | ||||
|---|---|---|---|---|
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 3 shares | 34 USD notional · <0.001% of shares out |
| 30 Sep 2026 | Financials | Total assets | 697.7M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 496.2M USD | at period end |
| 31 Dec 2025 | Financials | Revenue | 123.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −38.6M USD | fiscal year |
What do people ask about Monte Rosa Therapeutics (GLUE)?
What did Monte Rosa Therapeutics shares close at?13.37
Monte Rosa Therapeutics closed at 13.37 USD on 28 Aug 2026, down 6.70% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Monte Rosa Therapeutics’ market cap?1.1B
Monte Rosa Therapeutics is worth 1.1B USD by market value as of 28 Aug 2026, which is the share price times the shares on issue from its SEC filings.
What is Monte Rosa Therapeutics’ revenue?123.7M
Monte Rosa Therapeutics reported revenue of 123.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Monte Rosa Therapeutics insiders bought or sold shares recently?1 sale
In the 90 days to 10 Nov 2026, Monte Rosa Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 2 Jan 2026, show no open-market purchase. See Insiders
Which funds own Monte Rosa Therapeutics?1 of 45
1 of the 45 funds we track reported a Monte Rosa Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARValuation computed from SEC EDGAR filings